Opportunity Information: Apply for PA 09 127
Apply for PA 09 127
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Multiplex Assay Development for Arthritis and Musculoskeletal and Skin Diseases (SBIR R43/R44)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.846 Arthritis, Musculoskeletal and Skin Diseases Research.
- This funding opportunity was created on Apr 6, 2009 and posted on Apr 6, 2009.
- Applicants must submit their applications by Sep 7, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity "Multiplex Assay Development for Arthritis and Musculoskeletal and Skin Diseases (SBIR R43/R44)" (Funding Opportunity Number PA-09-127) is a National Institutes of Health (NIH) Small Business Innovation Research (SBIR) solicitation aimed specifically at small business concerns that can advance multiplex biomarker testing for diseases in the arthritis, musculoskeletal, rheumatic, and skin disease space. The central focus is on developing and applying state-of-the-art multiplex assay technologies that can measure multiple candidate biomarkers at once, particularly using very small volumes of body fluids. In practical terms, the opportunity is trying to push tools and platforms that can profile panels of biomarkers efficiently and sensitively, which is often critical in conditions where patient samples may be limited or where repeated sampling is desirable for monitoring disease activity, progression, or treatment response.
This is a discretionary grant program under the NIH umbrella, categorized in health research and tied to CFDA number 93.846 (Arthritis, Musculoskeletal and Skin Diseases Research). The intent is technology development with a clear biomedical application: creating multiplex assays that help researchers and clinicians better detect, stratify, and track these diseases through biomarker measurement. The FOA encourages proposals that not only invent or refine the multiplex technology itself, but also demonstrate its application to relevant biomarker candidates in these disease areas. The emphasis on "multiple candidate biomarkers" signals interest in panel-based approaches rather than single-analyte tests, reflecting the reality that complex inflammatory and autoimmune conditions often require multi-marker signatures to achieve useful sensitivity, specificity, or predictive value.
Applications are supported through SBIR grant mechanisms R43/R44, meaning the program accommodates Phase I projects (generally proof-of-concept and early feasibility), Phase II projects (full research and development and further validation), and Fast-Track applications (a combined submission that proposes Phase I and Phase II in one streamlined package). This structure is designed for small businesses building a product or platform, allowing a project to progress from early technical feasibility to more mature development, including assay optimization, analytical performance characterization, and potentially steps toward broader validation and readiness for adoption in research or translational settings.
Funding levels and the number of awards were not fixed in advance. Instead, awards under this FOA were contingent on available appropriations and on the volume and quality of submitted applications. The NIH indicated that both the number of awards and total dollars would vary depending on the merit, scope, duration, and proposed budgets of applications received. There is no cost sharing or matching requirement, which is typical for SBIR awards and lowers the barrier for small companies to participate.
Eligibility is limited to small businesses, consistent with SBIR rules. The opportunity was posted on April 6, 2009, and remained open through its original and final closing date of September 7, 2012, with an archive date of October 8, 2012. While the announcement is now archived, it provides a clear snapshot of NIH priorities during that period: accelerating multiplex assay innovation and translating those technical advances into practical biomarker measurement tools for arthritis, musculoskeletal, rheumatic, and skin diseases, especially in contexts where sample volume is constrained and multi-analyte readouts can provide more clinically or biologically meaningful information.
For full details, NIH provided an official guide notice link (http://grants.nih.gov/grants/guide/pa-files/PA-09-127.html) and directed applicants with access or linking issues to the NIH Office of Extramural Research (OER) webmaster contact (FBOWebmaster@OD.NIH.GOV).
Frequently Asked Questions (FAQs)
What is the name of this grant opportunity?
The opportunity is titled "Multiplex Assay Development for Arthritis and Musculoskeletal and Skin Diseases (SBIR R43/R44)."
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is PA-09-127.
Which agency is offering this opportunity?
This is a National Institutes of Health (NIH) solicitation.
What type of program is this (grant category)?
It is a discretionary grant program under the NIH umbrella and is categorized in health research.
What CFDA number is associated with this opportunity?
The opportunity is tied to CFDA number 93.846, "Arthritis, Musculoskeletal and Skin Diseases Research."
What is the main focus of the solicitation?
The central focus is developing and applying state-of-the-art multiplex assay technologies to measure multiple candidate biomarkers at once, particularly using very small volumes of body fluids, for arthritis, musculoskeletal, rheumatic, and skin diseases.
What does NIH mean here by "multiplex assay" development?
Based on the description, the solicitation is aimed at technologies and platforms that can profile panels of biomarkers efficiently and sensitively (multi-analyte testing), rather than measuring a single biomarker at a time.
Why is there an emphasis on measuring biomarkers from very small sample volumes?
The opportunity highlights scenarios where patient samples may be limited or where repeated sampling is desirable for monitoring disease activity, progression, or treatment response, making small-volume, high-information assays especially valuable.
Which disease areas are in scope for this opportunity?
The opportunity targets diseases in the arthritis, musculoskeletal, rheumatic, and skin disease space.
Is this opportunity focused on single biomarkers or biomarker panels?
The language emphasizes "multiple candidate biomarkers" and panel-based approaches, reflecting interest in multi-marker signatures rather than single-analyte tests.
What kinds of projects does the FOA encourage?
The FOA encourages proposals that (1) invent or refine multiplex assay technology and (2) demonstrate application of the technology to relevant biomarker candidates in the targeted disease areas.
What SBIR mechanisms are used for funding under this opportunity?
Applications are supported through SBIR grant mechanisms R43/R44.
Does this solicitation support Phase I SBIR projects?
Yes. The structure accommodates Phase I projects, described as generally focused on proof-of-concept and early feasibility.
Does this solicitation support Phase II SBIR projects?
Yes. The structure accommodates Phase II projects, described as full research and development and further validation.
Are Fast-Track applications allowed under this FOA?
Yes. The opportunity allows Fast-Track applications, which are combined submissions proposing Phase I and Phase II in one package.
What is the overall development pathway implied by the FOA?
The solicitation is framed for small businesses building a product or platform, progressing from early technical feasibility (Phase I) to more mature development (Phase II), including assay optimization and analytical performance characterization, and potentially steps toward broader validation and readiness for adoption in research or translational settings.
Who is eligible to apply?
Eligibility is limited to small businesses, consistent with SBIR rules.
Is cost sharing or matching required?
No. The NIH indicated there is no cost sharing or matching requirement.
How much funding is available and how many awards will be made?
Funding levels and the number of awards were not fixed in advance. Awards were contingent on available appropriations and on the volume and quality of submitted applications. NIH noted that award numbers and total dollars could vary depending on merit, scope, duration, and proposed budgets.
When was this opportunity posted?
The opportunity was posted on April 6, 2009.
What were the closing dates for this FOA?
The FOA remained open through its original and final closing date of September 7, 2012.
Is this funding opportunity still active?
No. The announcement is archived. It also lists an archive date of October 8, 2012.
Where can I find the official NIH posting for this FOA?
The official guide notice link provided is http://grants.nih.gov/grants/guide/pa-files/PA-09-127.html
Who should be contacted if there are access or linking issues with the NIH page?
NIH directed applicants with access or linking issues to contact the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
What NIH priority does this archived FOA reflect?
Based on the description, it reflects NIH interest (during that period) in accelerating multiplex assay innovation and translating those advances into practical biomarker measurement tools for arthritis, musculoskeletal, rheumatic, and skin diseases, especially when sample volume is constrained and multi-analyte readouts can be more informative.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Health
Next opportunity: Pilot and Feasibility Studies in Preparation for Drug Abuse Prevention Trials (R34)
Previous opportunity: Improved Public Policy Discourse in Georgia
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 09 127
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 09 127) also looked into and applied for these:
| Funding Opportunity |
|---|
| Preventing Complications of Bleeding Disorders through Health Education and Outreach Apply for CDC RFA DD09 905 Funding Number: CDC RFA DD09 905 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $750,000 |
| Hepatitis C Cooperative Research Centers (U19) Apply for RFA AI 09 025 Funding Number: RFA AI 09 025 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| EIS Ongoing Expansion Funds for Current Part C Grantees Apply for HRSA 09 219 Funding Number: HRSA 09 219 Agency: Health Resources and Services Administration Category: Health Funding Amount: $200,000 |
| Service Area Competitions Apply for HRSA 09 225 Funding Number: HRSA 09 225 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Research on Psychopathology In Intellectual Disabilities (Mental Retardation) (R01) Apply for PA 09 150 Funding Number: PA 09 150 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Basic Research on HIV Persistence (R01) Apply for PA 09 152 Funding Number: PA 09 152 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| International Centers of Excellence for Malaria Research (U19) Apply for RFA AI 09 017 Funding Number: RFA AI 09 017 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Promoting the Health of People with Clotting Disorders Apply for CDC RFA DD09 904 Funding Number: CDC RFA DD09 904 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $600,000 |
| Promoting Education and Outreach of Persons with Hereditary Blood Disorders Identifying Patients with Diamond Blackfan Anemia Apply for CDC RFA DD09 906 Funding Number: CDC RFA DD09 906 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $175,000 |
| Long Lasting Insecticide Treated Nets (LLINs) RFA Apply for M OAA GH 09 847 Funding Number: M OAA GH 09 847 Agency: Agency for International Development Category: Health Funding Amount: $100,000,000 |
| International Programs to Prevent and Control Micronutrient Malnutrition Apply for CDC RFA DP09 911 Funding Number: CDC RFA DP09 911 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $800,000 |
| Reducing Risks for an Alcohol Exposed Pregnancy (AEP) in High Risk Women Attending Sexually Transmitted Diseases (STD) Clinics in Urban Settings Apply for CDC RFA DD09 908 Funding Number: CDC RFA DD09 908 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $275,000 |
| Surveillance of Fetal Alcohol Syndrome (FAS) Utilizing the Infrastructure of Existing Surveillance Programs Apply for CDC RFA DD09 910 Funding Number: CDC RFA DD09 910 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $250,000 |
| Collaborative R01s for Clinical and Services Studies of Mental Disorders, AIDS and Alcohol Use Disorders (R01) Apply for PAR 09 153 Funding Number: PAR 09 153 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Early Diagnosis Cooperative Agreements Apply for CDC RFA PS09 9133 Funding Number: CDC RFA PS09 9133 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| Community Health Projects Related to Brownfield/Land Reuse Apply for CDC RFA TS09 904 Funding Number: CDC RFA TS09 904 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $75,000 |
| Translational Tools for Clinical Studies of CAM Interventions (SBIR R43/R44) Apply for RFA AT 09 004 Funding Number: RFA AT 09 004 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIOSH Small Research Grant Program (R03) Apply for PAR 09 138 Funding Number: PAR 09 138 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $50,000 |
| NIOSH Exploratory and/or Developmental Grant Program(R21) Apply for PAR 09 139 Funding Number: PAR 09 139 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| Early Hearing Detection and Intervention (EHDI) Tracking, Surveillance and Integration Apply for CDC RFA DD09 903 Funding Number: CDC RFA DD09 903 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 09 127", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.